Objective: To examine the effect of a low dose (10 mg) of methylphenidate on cognitive performance, visuospatial working memory (VSWM) and gaze behaviour capabilities in healthy adults.
Methods: This randomised, double-blind, placebo-controlled and crossover study examined the effects of 10 mg methylphenidate on cognitive performance, VSWM and gaze behaviour. Fixation duration and rate, gaze transition entropy, and stationary gaze entropy were used to quantify visual scanning efficiency in 25 healthy adults (36% female, mean ± SD age = 33.
Objective: To conduct a systematic review and meta-analysis of the facilitators of and barriers to the acceptance and use of digital health technology by health workers in low- and middle-income countries.
Methods: We searched several databases for relevant articles published until 25 April 2024. We extracted data on four unified theories of acceptance and use of technology factors (performance expectancy, effort expectancy, social influence and facilitating conditions) and six additional factors (attitude, habit, incentive, risk, trust and self-efficacy); how these affected the outcomes of behavioural intention and actual use; and the strength of association if reported.
Objective: To estimate inter-center variation (ICV) in hospital length of stay (LOS) and oral feeding at discharge among infants with gastroschisis.
Study Design: The Children's Hospitals Neonatal Consortium's (CHNC) database was used to identify hospitalized survivors with gastroschisis. Two outcomes were evaluated: LOS and discharge without tube feedings.
Introduction: China faces the dual challenge of high air pollution and an increasing burden of cardiovascular disease (CVD). We aimed to estimate the healthcare costs associated with CVD and the quality-adjusted life years (QALYs) under scenarios of improved air quality in China.
Methods: A health prediction model was developed to estimate 10-year CVD-related costs and QALY associated with PM2.
Purpose: The inclusion of ranibizumab biosimilars into National Health Service England commissioning recommendations published in 2022 created a need for expert guidance to optimize treatment outcomes in patients with neovascular age-related macular degeneration (nAMD) who otherwise may not have received first-line ranibizumab. This article provides a consensus treatment pathway supporting timely identification and management of a suboptimal response to these therapies, thereby aiming to facilitate clinically meaningful outcomes and efficient management of service capacity under specific circumstances where ranibizumab biosimilars may be initiated as a first-line treatment.
Methods: Two structured round-table meetings of UK medical retina specialists were held in person and virtually on September 22 and November 3, 2022, respectively.